180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced it has named Quan A. Vu to the role of chief operating officer/chief business officer. Vu is a highly versatile and accomplished strategy, corporate/business development, finance and operations executive with 20 years of “hands-on” biopharma experience. A consummate dealmaker and persuasive negotiator, he has a demonstrated history of prospecting, evaluating, structuring and closing transactions that augment both organizational and shareholder value and orchestrating domestic and international win-win solutions. “I’m excited to welcome Quan to our management team,” 180 Life Sciences CEO Dr. James Woody said in the news release. “With his sound understanding of pipeline development, commercial assessment and go-to-market strategies, I believe he will add meaningful value to our efforts to bring novel drugs that fulfill unmet needs to market. Importantly, he has a very defined track record of success in both in-licensing, out-licensing, co-development and mergers and acquisitions.”
To view the full press release, visit https://ibn.fm/fRUtw
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor). For more information, visit the company’s website at www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.